Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 1, 2012, Pages 1-19

  Vigeveno, René M ^a   Wiebenga, Oliver T ^a   Wattjes, Mike P ^a   Geurts, Jeroen J G ^a   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

functional adaptation; gray matter imaging; inflammation; multiple sclerosis; neurodegeneration; quantitative MRI

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

BRAIN ATROPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; TREATMENT PLANNING; WHITE MATTER LESION;

BRAIN; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84862731075     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23578     Document Type: Review

References (222)

1. Alonso A, Hernan MA,. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-135.
2. Compston A, Coles A,. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
3. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
4. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862. (Pubitemid 47347319)
5. Bush WS, Sawcer SJ, De Jager PL, et al. Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am J Hum Genet 2010; 86: 621-625.
6. Ebers GC, Sadovnick AD, Dyment DA, Yee IM, Willer CJ, Risch N,. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004; 363: 1773-1774. (Pubitemid 38698382)
7. Ascherio A, Munger KL,. Environmental risk factors for multiple sclerosis: Part I. The role of infection. Ann Neurol 2007; 61: 288-299. (Pubitemid 46676728)
8. Ascherio A, Munger KL, Simon KC,. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612.
9. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-1859.
10. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV,. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 2010; 5.
11. Hawkes CH,. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 2007; 13: 610-615. (Pubitemid 46939526)
12. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A,. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838. (Pubitemid 44969183)
13. Koch M, Kingwell E, Rieckmann P, Tremlett H,. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73: 1996-2002.
14. Koch M, Kingwell E, Rieckmann P, Tremlett H,. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1039-1043.
15. Ramsaransing GS, De Keyser J,. Benign course in multiple sclerosis: a review. Acta Neurol Scand 2006; 113: 359-369. (Pubitemid 44046321)
16. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG,. Medical progress: multiple sclerosis. N Engl J Med 2000; 343: 938-952.
17. Frohman EM, Racke MK, Raine CS,. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955.
18. Sospedra M, Martin R,. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747. (Pubitemid 40563183)
19. Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R,. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009; 282: 12-20.
20. Bo L, Geurts JJ, Mork SJ, van der Valk P,. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 2006; 183: 48-50.
21. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128 (Pt 11): 2705-2712. (Pubitemid 41552953)
22. Barkhof F,. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239-245. (Pubitemid 34596884)
23. Benedict RH, Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006; 63: 1301-1306. (Pubitemid 44379833)
24. Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008; 255: 581-586.
25. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S,. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62: 586-590. (Pubitemid 38252800)
26. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 2002; 195: 103-109. (Pubitemid 34202286)
27. Amato MP, Ponziani G, Siracusa G, Sorbi S,. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58: 1602-1606. (Pubitemid 32963224)
28. Rao SM, Leo GJ, Bernardin L, Unverzagt F,. Cognitive dysfunction in multiple-sclerosis: 1. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
29. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; 1: CD001331.
30. Martinelli BF, Rovaris M, Capra R, Comi G,. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005; 1: CD002127.
31. Lopez-Diego RS, Weiner HL,. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008; 7: 909-925.
32. Ge Y,. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 2006; 27: 1165-1176. (Pubitemid 44897620)
33. Lovblad KO, Anzalone N, Dorfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010; 31: 983-989.
34. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62: 226-233. (Pubitemid 38167129)
35. Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2003; 2: 555-562. (Pubitemid 36994995)
36. O'Riordan JI, Losseff NA, Phatouros C, et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry 1998; 64: 353-357. (Pubitemid 28159840)
37. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
38. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
39. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
40. Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA,. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005; 236: 254-260. (Pubitemid 40853320)
41. Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011; 76: 418-424.
42. Filippi M, Rocca MA, Calabrese M, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 2010; 75: 1988-1994.
43. Keiper MD, Grossman RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T. AJNR Am J Neuroradiol 1998; 19: 1489-1493. (Pubitemid 30431043)
44. Bachmann R, Reilmann R, Schwindt W, Kugel H, Heindel W, Kramer S,. FLAIR imaging for multiple sclerosis: a comparative MR study at 1.5 and 3.0 Tesla. Eur Radiol 2006; 16: 915-921. (Pubitemid 43380251)
45. Nielsen K, Rostrup E, Frederiksen JL, et al. Magnetic resonance imaging at 3.0 tesla detects more lesions in acute optic neuritis than at 1.5 tesla. Invest Radiol 2006; 41: 76-82. (Pubitemid 44406202)
46. Sicotte NL, Voskuhl RR, Bouvier S, Klutch R, Cohen MS, Mazziotta JC,. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 2003; 38: 423-427. (Pubitemid 36791336)
47. Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006; 16: 2067-2073. (Pubitemid 44193191)
48. Kollia K, Maderwald S, Putzki N, et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR Am J Neuroradiol 2009; 30: 699-702.
49. Tallantyre EC, Morgan PS, Dixon JE, et al. 3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesions. J Magn Reson Imaging 2010; 32: 971-977.
50. Ge Y, Zohrabian VM, Grossman RI,. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol 2008; 65: 812-816. (Pubitemid 351831461)
51. Tallantyre EC, Morgan PS, Dixon JE, et al. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Invest Radiol 2009; 44: 491-494.
52. Kilsdonk ID, Barkhof F, Wattjes MP,. 2010 revisions to mcDonald criteria for diagnosis of multiple sclerosis: impact of 3-tesla magnetic resonance imaging. Ann Neurol 2011; 70: 182-183.
53. Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006; 27: 1794-1798. (Pubitemid 44413574)
54. Wattjes MP, Harzheim M, Lutterbey GG, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol 2008; 255: 1159-1163.
55. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 2006; 5: 841-852. (Pubitemid 44715819)
56. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011; 82: 126-135.
57. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121: 944-949. (Pubitemid 36841781)
58. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247-254.
59. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998; 43: 332-339. (Pubitemid 28113596)
60. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001; 57: 1253-1258. (Pubitemid 32947385)
61. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-377. (Pubitemid 32106796)
62. Filippi M,. Predictive value of MRI findings in multiple sclerosis. Lancet Neurol 2002; 1: 9. (Pubitemid 37159191)
63. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A,. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 41-46. (Pubitemid 38100525)
64. Mainero C, Caramia F, Pozzilli C, et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 2004; 21: 858-867. (Pubitemid 38314947)
65. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
66. Comi G, Filippi M, Wolinsky JS,. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297. (Pubitemid 32202781)
67. Filippi M, Rovaris M, Inglese M, Barkhof F, De SN, Smith S, Comi G,. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496. (Pubitemid 39410414)
68. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294. (Pubitemid 26100751)
69. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. (Pubitemid 44563835)
70. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397. (Pubitemid 47189673)
71. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684. (Pubitemid 43739821)
72. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]. Neurology 2001; 57 (Suppl 5): S46-S53. (Pubitemid 34015226)
73. Li DK, Paty DW,. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999; 46: 197-206. (Pubitemid 29382876)
74. Paty DW, Li DK,. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667. (Pubitemid 23121952)
75. Rovaris M, Comi G, Rocca MA, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 2007; 13: 502-508. (Pubitemid 46796510)
76. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43: 79-87. (Pubitemid 28124651)
77. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
78. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
79. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944-953. (Pubitemid 44454583)
80. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P,. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65: 268-275.
81. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P,. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010; 75: 302-309.
82. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64: 236-240.
83. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68: 1390-1401. (Pubitemid 46659091)
84. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002; 59: 688-694.
85. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-144.
86. Korteweg T, Rovaris M, Neacsu V, et al. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler 2009; 15: 465-471.
87. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-490. (Pubitemid 34260778)
88. Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003; 53: 718-724. (Pubitemid 36622508)
89. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256: 405-415.
90. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E,. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555. (Pubitemid 39319345)
91. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V,. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 2005;(Suppl 4): S174-S178. (Pubitemid 43085206)
92. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293.
93. Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484. (Pubitemid 351943860)
94. Rio J, Comabella M, Montalban X,. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553-560.
95. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A,. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
96. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68: 392-395.
97. Coffey CE, Wilkinson WE, Parashos IA, et al. Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology 1992; 42 (Pt 1): 527-536.
98. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO,. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 1994; 51: 874-887. (Pubitemid 24286042)
99. Bermel RA, Bakshi R,. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158-170. (Pubitemid 43107851)
100. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-1876.
101. Filippi M, Rocca MA,. Conventional MRI in multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1): 3S-9S. (Pubitemid 46558261)
102. Barkhof F, McGowan JC, van Waesberghe JH, Grossman RI,. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J Neurol Neurosurg Psychiatry 1998; 64 (Suppl 1): S77-S79. (Pubitemid 28274442)
103. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126 (Pt 8): 1782-1789. (Pubitemid 36917337)
104. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455-459. (Pubitemid 29371143)
105. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G,. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731-733. (Pubitemid 32783013)
106. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-1288. (Pubitemid 28240340)
107. Fazekas F, Ropele S, Enzinger C, Seifert T, Strasser-Fuchs S,. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler 2002; 8: 479-484. (Pubitemid 35396396)
108. Laule C, Vavasour IM, Whittall KP, et al. Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 2003; 250: 924-931. (Pubitemid 37041022)
109. Chen JT, Kuhlmann T, Jansen GH, et al. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 2007; 36: 1152-1158. (Pubitemid 47001724)
110. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL,. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008; 63: 254-262. (Pubitemid 351355304)
111. Ciccarelli O, Werring DJ, Barker GJ, et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration. J Neurol 2003; 250: 287-292. (Pubitemid 36399267)
112. Giorgio A, Palace J, Johansen-Berg H, et al. Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis. J Magn Reson Imaging 2010; 31: 309-316.
113. Raz E, Cercignani M, Sbardella E, et al. Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2010; 254: 227-234.
114. Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 2009; 44: 1397-1403.
115. Sajja BR, Wolinsky JS, Narayana PA,. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009; 19: 45-58.
116. Tiberio M, Chard DT, Altmann DR, et al. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 2006; 253: 224-230. (Pubitemid 43255895)
117. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11: 646-651. (Pubitemid 41685134)
118. Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 2011; 32: 85-91.
119. Geurts JJ, Bo L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007; 66: 819-827. (Pubitemid 47360957)
120. Gilmore CP, Bo L, Owens T, Lowe J, Esiri MM, Evangelou N,. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol 2006; 16: 202-208. (Pubitemid 44175234)
121. Huitinga I, De Groot CJ, van der Valk P, Kamphorst W, Tilders FJ, Swaab DF,. Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol 2001; 60: 1208-1218. (Pubitemid 33117101)
122. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P,. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005; 64: 1101-1107.
123. Gilmore CP, Donaldson I, Bo L, Owens T, Lowe J, Evangelou N,. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 2009; 80: 182-187.
124. Simon B, Schmidt S, Lukas C, et al. Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol 2010; 20: 1675-1683.
125. Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F,. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005; 26: 572-577. (Pubitemid 43085960)
126. Metcalf M, Xu D, Okuda DT, et al. High-resolution phased-array MRI of the human brain at 7 tesla: initial experience in multiple sclerosis patients. J Neuroimaging 2010; 20: 141-147.
127. Schmierer K, Parkes HG, So PW, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain 2010; 133 (Pt 3): 858-867.
128. Pouwels PJ, Kuijer JP, Mugler JP III, Guttmann CR, Barkhof F,. Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. Radiology 2006; 241: 873-879. (Pubitemid 46190555)
129. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA,. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007; 28: 1645-1649. (Pubitemid 47598132)
130. Calabrese M, Filippi M, Rovaris M, et al. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage 2008; 42: 1324-1328.
131. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66: 1144-1150.
132. Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009; 72: 1330-1336.
133. Calabrese M, Rocca MA, Atzori M, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol 2010; 67: 376-383.
134. Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findings. Radiology 2008; 246: 880-886.
135. Tovar-Moll F, Evangelou IE, Chiu AW, et al. Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. AJNR Am J Neuroradiol 2009; 30: 1380-1386.
136. Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology 2001; 56: 926-933. (Pubitemid 32290810)
137. Filippi M, Bozzali M, Comi G,. Magnetization transfer and diffusion tensor MR imaging of basal ganglia from patients with multiple sclerosis. J Neurol Sci 2001; 183: 69-72. (Pubitemid 32141075)
138. Griffin CM, Chard DT, Ciccarelli O, et al. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis. Mult Scler 2001; 7: 290-297. (Pubitemid 33026254)
139. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006; 129 (Pt 10): 2628-2634. (Pubitemid 44522096)
140. Dehmeshki J, Chard DT, Leary SM, et al. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol 2003; 250: 67-74. (Pubitemid 36206687)
141. Fernando KT, Tozer DJ, Miszkiel KA, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005; 128 (Pt 12): 2911-2925. (Pubitemid 41746644)
142. Rocca MA, Mastronardo G, Rodegher M, Comi G, Filippi M,. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 1999; 20: 821-827. (Pubitemid 29536257)
143. Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH,. Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Mult Scler 2007; 13: 483-489. (Pubitemid 46796508)
144. Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ,. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007: 37: 253-261. (Pubitemid 47068988)
145. Hayton T, Furby J, Smith KJ, et al. Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 2009; 256: 427-435.
146. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M,. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129 (Pt 10): 2620-2627. (Pubitemid 44522095)
147. Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson AJ,. Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008; 65: 1454-1459.
148. Geurts JJ, Reuling IE, Vrenken H, et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006; 55: 478-483. (Pubitemid 43352544)
149. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125 (Pt 10): 2342-2352.
150. Sharma R, Narayana PA, Wolinsky JS,. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 2001; 7: 221-226. (Pubitemid 32780691)
151. Sijens PE, Mostert JP, Oudkerk M, De Keyser J,. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006; 16: 489-495. (Pubitemid 43149650)
152. Caramanos Z, DiMaio S, Narayanan S, Lapierre Y, Arnold DL,. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis. J Neurol Sci 2009; 282: 72-79.
153. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003; 24: 1941-1945. (Pubitemid 37444842)
154. Ropele S, de Graaf W, Khalil M, et al. MRI assessment of iron deposition in multiple sclerosis. J Magn Reson Imaging 2011; 34: 13-21.
155. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R,. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007; 4: 371-386. (Pubitemid 46962416)
156. Bakshi R, Benedict RH, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002; 59: 62-68. (Pubitemid 34052557)
157. Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009; 15: 678-686.
158. Ceccarelli A, Rocca MA, Neema M, et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010; 16: 39-44.
159. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 1048-1054.
160. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005; 62: 1371-1376. (Pubitemid 41352053)
161. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127 (Pt 5): 1101-1107. (Pubitemid 38623045)
162. Fisher E, Lee JC, Nakamura K, Rudick RA,. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255-265.
163. Rudick RA, Lee JC, Nakamura K, Fisher E,. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009; 282: 106-111.
164. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007; 254: 1212-1220. (Pubitemid 350112349)
165. Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 2010; 74: 321-328.
166. Pellicano C, Gallo A, Li X, et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol 2010; 67: 447-453.
167. Audoin B, Zaaraoui W, Reuter F, et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 690-695.
168. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D,. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008; 79: 1236-1244.
169. Tao G, Datta S, He R, Nelson F, Wolinsky JS, Narayana PA,. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci 2009; 282: 39-46.
170. Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain 2008; 131 (Pt 4): 1134-1141. (Pubitemid 351499428)
171. Anderson VM, Fisniku LK, Khaleeli Z, et al. Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Mult Scler 2010; 16: 1083-1090.
172. Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M,. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010; 257: 463-469.
173. Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 2007; 36: 1294-1300. (Pubitemid 47007715)
174. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808-817. (Pubitemid 351294716)
175. Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O,. Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. Hum Brain Mapp 2009; 30: 2852-2861.
176. Fox MD, Greicius M,. Clinical applications of resting state functional connectivity. Front Syst Neurosci 2010; 4: 19.
177. Beckmann CF, DeLuca M, Devlin JT, Smith SM,. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1001-1013. (Pubitemid 41672861)
178. Cordes D, Haughton VM, Arfanakis K, et al. Mapping functionally related regions of brain with functional connectivity MR imaging. AJNR Am J Neuroradiol 2000; 21: 1636-1644.
179. Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A; 103: 13848-13853.
180. Lowe MJ, Mock BJ, Sorenson JA,. Functional connectivity in single and multislice echoplanar imaging using resting-state fluctuations. Neuroimage 1998; 7: 119-132. (Pubitemid 28355547)
181. Salvador R, Suckling J, Coleman MR, Pickard JD, Menon D, Bullmore E,. Neurophysiological architecture of functional magnetic resonance images of human brain. Cereb Cortex 2005; 15: 1332-1342.
182. van den Heuvel MP, Mandl RC, Kahn RS, Hulshoff Pol HE,. Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain. Hum Brain Mapp 2009; 30: 3127-3141.
183. Hampson M, Peterson BS, Skudlarski P, Gatenby JC, Gore JC,. Detection of functional connectivity using temporal correlations in MR images. Hum Brain Mapp 2002; 15: 247-262. (Pubitemid 34234789)
184. Fox MD, Corbetta M, Snyder AZ, Vincent JL, Raichle ME,. Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. Proc Natl Acad Sci U S A 2006; 103: 10046-10051. (Pubitemid 43993620)
185. Zhang D, Snyder AZ, Fox MD, Sansbury MW, Shimony JS, Raichle ME,. Intrinsic functional relations between human cerebral cortex and thalamus. J Neurophysiol 2008; 100: 1740-1748.
186. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME,. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A 2005; 102: 9673-9678. (Pubitemid 40981739)
187. Greicius MD, Krasnow B, Reiss AL, Menon V,. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A 2003; 100: 253-258. (Pubitemid 36078061)
188. Korsholm K, Madsen KH, Frederiksen JL, Skimminge A, Lund TE,. Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas. Brain 2007; 130 (Pt 5): 1244-1253. (Pubitemid 47355949)
189. Jenkins TM, Toosy AT, Ciccarelli O, et al. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol 2010; 67: 99-113.
190. Filippi M, Rocca MA, Mezzapesa DM, et al. Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Hum Brain Mapp 2004; 21: 108-117. (Pubitemid 38167035)
191. Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005; 4: 618-626. (Pubitemid 41317296)
192. Pantano P, Mainero C, Lenzi D, et al. A longitudinal fMRI study on motor activity in patients with multiple sclerosis. Brain 2005; 128 (Pt 9): 2146-2153. (Pubitemid 41253281)
193. Valsasina P, Agosta F, Absinta M, Sala S, Caputo D, Filippi M,. Cervical cord functional MRI changes in relapse-onset MS patients. J Neurol Neurosurg Psychiatry 2010; 81: 405-408.
194. Agosta F, Valsasina P, Absinta M, Sala S, Caputo D, Filippi M,. Primary progressive multiple sclerosis: tactile-associated functional MR activity in the cervical spinal cord. Radiology 2009; 253: 209-215.
195. Gilmore CP, DeLuca GC, Bo L, et al. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol 2009; 19: 642-649.
196. Audoin B, Au Duong MV, Ranjeva JP, et al. Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. Hum Brain Mapp 2005; 24: 216-228. (Pubitemid 40327848)
197. Lazeron RH, Rombouts SA, de Sonneville L, Barkhof F, Scheltens P,. A paced visual serial addition test for fMRI. J Neurol Sci 2003; 213: 29-34. (Pubitemid 36842863)
198. Staffen W, Mair A, Zauner H, et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002; 125 (Pt 6): 1275-1282. (Pubitemid 34587137)
199. Sumowski JF, Wylie GR, DeLuca J, Chiaravalloti N,. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain 2010; 133 (Pt 2): 362-374.
200. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 2010; 74: 1252-1259.
201. Bonavita S, Gallo A, Sacco R, et al. Distributed changes in default-mode resting-state connectivity in multiple sclerosis. Mult Scler 2011; 17: 411-422.
202. Bobholz JA, Rao SM, Lobeck L, et al. fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume. Neurology 2006; 67: 1640-1645. (Pubitemid 44747937)
203. Lazeron RH, Rombouts SA, Scheltens P, Polman CH, Barkhof F,. An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. Mult Scler 2004; 10: 549-555. (Pubitemid 39207229)
204. Genova HM, Hillary FG, Wylie G, Rypma B, DeLuca J,. Examination of processing speed deficits in multiple sclerosis using functional magnetic resonance imaging. J Int Neuropsychol Soc 2009; 15: 383-393.
205. Nebel K, Wiese H, Seyfarth J, et al. Activity of attention related structures in multiple sclerosis patients. Brain Res 2007; 1151: 150-160. (Pubitemid 46709869)
206. Penner IK, Rausch M, Kappos L, Opwis K, Radu EW,. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003; 250: 461-472. (Pubitemid 36459754)
207. Au Duong MV, Audoin B, Boulanouar K, et al. Altered functional connectivity related to white matter changes inside the working memory network at the very early stage of MS. J Cereb Blood Flow Metab 2005; 25: 1245-1253. (Pubitemid 41348727)
208. Lee M, Reddy H, Johansen-Berg H, et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann Neurol 2000; 47: 606-613. (Pubitemid 30261896)
209. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002; 58: 866-872. (Pubitemid 34242060)
210. Giorgio A, Portaccio E, Stromillo ML, et al. Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Mult Scler 2010; 16: 1326-1334.
211. Rocca MA, Ceccarelli A, Rodegher M, et al. Preserved brain adaptive properties in patients with benign multiple sclerosis. Neurology 2010; 74: 142-149.
212. Cerasa A, Fera F, Gioia MC, et al. Adaptive cortical changes and the functional correlates of visuo-motor integration in relapsing-remitting multiple sclerosis. Brain Res Bull 2006; 69: 597-605. (Pubitemid 43728751)
213. Rocca MA, Gavazzi C, Mezzapesa DM, et al. A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. Neuroimage 2003; 19: 1770-1777. (Pubitemid 37025872)
214. Ceccarelli A, Rocca MA, Valsasina P, et al. Structural and functional magnetic resonance imaging correlates of motor network dysfunction in primary progressive multiple sclerosis. Eur J Neurosci 2010; 31: 1273-1280.
215. Bonzano L, Pardini M, Mancardi GL, Pizzorno M, Roccatagliata L,. Structural connectivity influences brain activation during PVSAT in multiple sclerosis. Neuroimage 2009; 44: 9-15.
216. Rocca MA, Pagani E, Absinta M, et al. Altered functional and structural connectivities in patients with MS: a 3-T study. Neurology 2007; 69: 2136-2145. (Pubitemid 350294694)
217. Rocca MA, Valsasina P, Ceccarelli A, et al. Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp 2009; 30: 276-290.
218. He Y, Dagher A, Chen Z, et al. Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain 2009; 132 (Pt 12): 3366-3379.
219. Shu N, Liu Y, Li K, et al. Diffusion tensor tractography reveals disrupted topological efficiency in white matter structural networks in multiple sclerosis. Cereb Cortex 2011; 21: 2565-2577.
220. Guye M, Bettus G, Bartolomei F, Cozzone PJ,. Graph theoretical analysis of structural and functional connectivity MRI in normal and pathological brain networks. MAGMA 2010; 23: 409-421.
221. Bullmore E, Sporns O,. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci 2009; 10: 186.
222. Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging 2008; 27: 726-731. (Pubitemid 351508085)